JonesTrading analyst Justin Walsh maintained a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report) today and set a price target of $24.00. The company's shares closed last Friday at $9.73.According to TipRanks, Walsh is an analyst with an average return of -33.4% and a 24.59% success rate. Walsh covers the Healthcare sector, focusing on stocks such as POINT Biopharma Global, Plus Therapeutics, and Actinium Pharmaceuticals.Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $27.60, implying a 183.66% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $53.00 price target.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-receives-a-buy-from-jonestrading-2?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Jan 2023 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Fév 2022 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals